Technology & Data Science for Enhanced Patient Care

JMSACL Logo

Editorial Board :JMSACL

Data Science

Dustin Bunch, PhD, DABCC
Nationwide Children's Hospital, Columbus, Ohio, United States

Data Science
Machine Learning
TDM
Metabolomics
Small Molecules
Clinical Implementation
Method Development & Validation

Dustin R. Bunch is the Assistant Director for Clinical Chemistry and Laboratory Informatics at Nationwide Children's Hospital. He completed his Clinical Chemistry Fellowship at Yale-New Haven Hospital where he was able to expand his data science abilities. Prior to his fellowship, he spent 10 years at the Cleveland Clinic as a research and development scientist for clinical mass spectrometry. He is Chair-Elect for the Ohio Valley section of AACC and chair for the regional Ohio Collaborative Laboratory Conference, a joint effort of AACC, ASCLS, and CLMA.
Randall Julian, PhD
Indigo BioAutomation, Carmel, Indiana, United States
Data Science
Machine Learning

Randy Julian is the Founder and CEO of Indigo BioAutomation. Randy earned a Ph.D. in Chemistry from Purdue University. Dr. Julian worked for 14 years at Eli Lilly using mass spectrometry in natural product drug discovery, high throughput screening for RNA anti-viral compounds, and proteomics and metabolomics in animal models. Randy founded Indigo as a spin-out of Lilly. Indigo develops software that uses machine learning techniques to analyze data from laboratories across the US automatically. Dr. Julian is also is an Adjunct Professor of Chemistry at Purdue.
Stephen Master, MD, PhD
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Data Science
Proteomics
Metabolomics

Stephen Master received his undergraduate degree in Molecular Biology from Princeton University, and subsequently obtained his MD and PhD from the University of Pennsylvania School of Medicine. After residency in Clinical Pathology at Penn, he stayed on as a faculty member with a research focus in mass spectrometry-based proteomics as well as extensive course development experience in bioinformatics. After time as an Associate Professor of Pathology and Laboratory Medicine at Weill Cornell Medicine in New York City, where he served as Director of the Central Lab and Chief of Clinical Chemistry Laboratory Services, he took a position at the Children's Hospital of Philadelphia at Chief of Lab Medicine. One of his current interests is in the applications of bioinformatics and machine learning for the development of clinical laboratory assays. He would play with R for fun even if he weren't getting paid, but he would appreciate it if you didn't tell that to his department chair.

Endocrinology

Giorgia Antonelli, PhD
University of Padova, Padova, Italy
Endocrinology
Clinical Implementation
Method Development & Validation
Sample Prep
Steroids

Giorgia graduated in 2004 with a masters degree in Pharmaceuticals Technology and Chemistry from the University of Padova (Italy). In 2008, she finished her PhD in Cellular and Molecular Pharmacology. In 2018 she obtained the National Academic qualification as Associate Professor in Clinical Biochemistry and Clinical Molecular Biology. Following her first experience in a research laboratory in 2011, she has since worked in a clinical laboratory on LC-MS/MS method validation, in particular for endocrinology applications. Her skills also include ISO15189 accreditation, especially for method verification and validation.
Daniel Holmes, MD, FRCPC
St. Paul’s Hospital, Vancouver, British Columbia, Canada

Endocrinology
Data Science
Small Molecules
Automation
Sample Prep

Daniel Holmes did his undergraduate training in Chemistry and Physics at the University of Toronto before deciding to pursue medicine as a career. He attended medical school at the University of British Columbia where pathology became his area of major interest. The strong influence of his academic mentors led him to enter the Medical Biochemistry residency training program at UBC. This allowed him to use his background knowledge of chemistry in application to medicine. Areas of clinical interest are diagnostic lipidology/endocrinology and research interests are in the utilization of mathematics and computer diagnostics to laboratory medicine.
Mark Kushnir, PhD
University of Utah and ARUP, Salt Lake City, Utah, United States

Endocrinology
Proteomics
Small Molecules
Biomarkers
Method Development & Validation
Sample Prep
Quantitative MS
Clinical Implementation

Mark Kushnir is Scientific Director, Mass Spectrometry R&D at ARUP Institute for Clinical and Experimental Pathology and Adjunct Assistant Professor at the Department of Pathology, University of Utah School of Medicine. He received PhD in Analytical Chemistry from Uppsala University (Uppsala, Sweden); his main areas of interest include development, application and clinical evaluation of novel mass spectrometry based clinical diagnostic methods for small molecule, protein and peptide biomarkers. He is author/coauthor of over 100 scientific peer reviewed publications.
Mirko Peitzsch, PhD
University Hospital Carl Gustav Carus at the TU Dresden, Dresden, Germany
Endocrinology
Small Molecules
Steroids
Metabolite Role and Activity

Mirko is working at the Institute for Clinical Chemistry and Laboratory Medicine (IKL) of the University Hospital Carl Gustav Carus Dresden, where as the head of the Experimental Mass Spectrometry unit, he is responsible for the development and application of LC-MS/MS based targeted and untargeted analysis. One focus in recent years has been the clinical application of LC-MS/MS based methods for determining adrenal hormones for diagnosis of various causes of secondary hypertension.

Glycomics

Chad Borges, PhD
Arizona State University, Tempe, Arizona, United States

Glycomics
Proteomics
Small Molecules
Sample Prep
Biomarkers
Method Development & Validation
Quantitative MS

Chad Borges is an associate professor at Arizona State University with appointments in the School of Molecular Sciences and The Biodesign Institute. He has a B.S. in chemistry and a Ph.D. in Analytical Toxicology. Though he has extensive experience in quantifying small molecules by mass spectrometry, his research interests currently reside in characterizing and quantifying protein post-translational modifications (PTMs) for biomedical purposes. This includes application of a new form of bottom-up glycomics known as glycan “node” analysis; developing molecular markers of biospecimen integrity; and quantification of PTMs as indicators of disease.
Manfred Wuhrer, PhD, Prof. dr.
Leiden University Medical Center, Leiden, The Netherlands

Glycomics
Glycoproteomics
PTMs

Manfred Wuhrer studied biochemistry at Regensburg University, and did a PhD in parasite glycobiology at Giessen University, both Germany. Since 2003 he is at the Leiden University Medical Center, the Netherlands, where he is currently heading the Center for Proteomics and Metabolomics. His key interests are the development of mass spectrometric methods for studying proteins and carbohydrates, and their application in biomedical research on cancer, autoimmune and infections diseases, with the aim of impacting patient care.

Imaging

Jörg Hanrieder, PhD
Sahlgrenska Hospital - University of Gothenburg, Gothenburg, Sweden

Imaging
Clinical Implementation
Biomarkers
Proteomics
Peptidomics
Lipidomics

I have a background in Chemistry (MS, Univ Leipzig, Germany) and a PhD in Neurochemistry (Uppsala Univ., Sweden). Currently, I am a group leader in Neurochemistry at Sahlgrenska Hospital - University of Gothenburg (Sweden) and the Institute of Neurology, UCL (UK). My background bridges key elements of analytical sciences with molecular neuroscience. In my lab, we employ state of the art mass spectrometry tools to understand key pathogenic mechanism of neurodegenerative diseases with the central aim to translate the outcomes of our research to applications critical in clinical neurology.
Wojciech Michno, PhD
Stanford University, Stanford, California, United States

Imaging
Proteomics
Lipidomics
Metabolomics
Pathology
Data Science
Clinical Implementation

During my PhD I worked with development and implementation of multimodal mass spectrometry approaches for analysis of neurodegenerative diseases, particularly Alzheimer’s disease, using animal and human subjects. My recent work focuses on cell-type specific multiomic analysis of brain development and disease, using human-derived in vitro organoids as a platform for clinical target identification (biomarkers) and treatment screening.
Nicole Strittmatter, PhD
Technical University of Munich, Munich, Germany

Imaging
Ambient Ionization
Metabolomics
Direct Infusion
Microbiology

I studied chemistry at the Justus-Liebig University in Giessen, specialising in Analytical Chemistry and Mass Spectrometry Applications. I subsequently performed my PhD studies with Prof Takats at Imperial College London (2012-2015), developing direct on sample applications for the characterisation and identification of microorganisms such as bacteria, fungi and mammalian cell lines. I joined AstraZeneca as a mass spectrometry imaging scientist in 2015, performing small molecule DESI and MALDI imaging as well as imaging mass cytometry studies to understand drug disposition, drug efficacy and safety and for systems-level tumour model characterisation studies. Expertise: Direct infusion MS techniques, MS imaging, metabolomics, ambient MS.

Instrumentation

Christopher Chouinard, PhD
Florida Institute of Technology, Melbourne, Florida, United States

Instrumentation
Steroids
Ion Mobility

I received my PhD from University of Florida in 2016, where I developed ion mobility-mass spectrometry (IM-MS) methods for steroids and vitamin D metabolites. I then worked as post-doctoral research at Pacific Northwest National Laboratory, building Structures for Loss Ion Manipulations (SLIM) ion mobility instrumentation for application in metabolomics and proteomics. Since 2018, I have been an Assistant Professor at Florida Institute of Technology. Work in my research group focuses on structurally selective reactions for improved characterization of steroids and other controlled substances with IM-MS.
Phillip Mach, PhD
U.S. Army Combat Capabilities Development Command Chemical Biological Center, Baltimore, Maryland, United States

Instrumentation
Data Science
Metabolomics
Proteomics

Dr. Phillip Mach is a Principle Investigator at the Combat Capabilities Development Command (CCDC) Chemical Biological Center (CBC). He leads research efforts in support of the U.S. Army and in developing new technologies and instrumentation supporting the warfighter. Phillip is working on biomarker discovery efforts via proteomic, metabolomic, and lipidomic mass spectrometry techniques in biofluids, culture, and organ-on-a-chip platforms. The group works to investigate host response, mechanism of action, and global ‘omics changes. He received a PhD from the University of North Texas in Analytical Chemistry, working on mass spectrometry instrument design.

Lipidomics

Anne Bendt, PhD
Singapore Lipidomics Incubator (SLING), National University of Singapore, Singapore

Lipidomics

Anne K Bendt studied Biology focusing on marine biotechnology (Greifswald University, Germany), followed by a PhD in Biochemistry (Cologne University, Germany) employing proteomics and transcriptomics. Driven by her fascination for infectious diseases, she joined the National University of Singapore (NUS) in 2004 to develop lipidomics tools for tuberculosis studies. She is now a Principal Investigator at the Life Sciences Institute, NUS, focussing on translation of mass spec technologies into clinical applications, and serving as the Associate Director of the Singapore Lipidomics Incubator (SLING) taking care of operations and commercialization.
Joshua Dubland, PhD
The University of British Columbia & BC Children’s Hospital, Vancouver, British Columbia, Canada

Lipidomics
Metabolomics
Small Molecules
Newborn Screening
Biomarkers
Clinical Implementation

Josh is a Laboratory Scientist in the Newborn Screening and Biochemical Genetics Laboratories at BC Children's Hospital in Vancouver, Canada. He has a BSc in Chemistry from Simon Fraser University and a MSc in Chemistry from the University of Toronto. After working in the clinical and pharmaceutical industry for 4 years Josh returned to academia and completed a PhD in Experimental Medicine from the University of British Columbia with a focus on cardiovascular disease. Josh is passionate about developing and implementing innovative analytical strategies in the clinical laboratory with a focus on mass spectrometry.
William Griffiths, PhD
Swansea University, Swansea, Wales, United Kingdom
Lipidomics
Metabolomics
Proteomics
Endocrinology
Steroids
Small Molecules
Imaging

The Griffiths – Wang research group is focused on the mass spectrometric analysis of lipids and proteins. Current projects involve the study of cholesterol biosynthesis and metabolism, particularly the formation of oxysterols and bile acids. New and improved methods for the identification, quantification, and characterization of bile acids, oxysterols, and other sterols and steroids, are being developed; and the involvement of these molecules in neurogenesis and immunity is being investigated. Complementary to this, proteomic techniques are being used to study biosynthetic and metabolizing enzymes in tissues and cells.
Robert Gurke, PhD
Goethe University Frankfurt, Frankfurt, Germany

Lipidomics
Metabolomics
Biomarkers
Clinical Implementation
Method Development & Validation

Robert Gurke received his diploma in chemistry at the Humboldt-University zu Berlin, Germany in 2012 followed by his doctoral thesis at the Technische Universität Dresden in 2016. After a short period as study director in a GLP-compliant bioanalytical company in Berlin he started working as research associate at the Institute of Clinical Pharmacology in Frankfurt under the guidance of Prof. Geisslinger. Mr Gurke is performing LC-MS/MS analysis since starting his doctoral thesis and gained broad experience in the field of developing and validating methods for the determination of exogenous and endogenous small molecules in different complex matrices.
Tiffany Thomas, PhD
Columbia University, New York City, New York, United States
Lipidomics
Metabolomics
Small Molecules
Fluxomics
Method Development & Validation

Dr. Thomas has over 20 years of mass spectrometry experience doing fluxomics, lipidomics, and metabolomics based experiments. She is the director of the New York Presbyterian Hospital/Columbia University Medical Center Biochemical Genetics Laboratory and is a Co-Director of the Laboratory of Transfusion Biology at Columbia University. She studies dietary factors of blood quality using high resolution mass spectrometry.

Metabolomics

Dennis Bernieh, PhD
University of Leicester, Leicester, United Kingdom

Metabolomics
TDM
Microsampling
Precision Medicine

Dennis Bernieh is a Postdoctoral Researcher with the Cardiovascular Science department of the University of Leicester. He obtained his PhD in Applied Bioanalysis from De Montfort University. His research spans the application of novel bioanalytical technologies to solving challenging health problems particularly associated with the use of mass spectrometry for the bioanalysis of biomarkers, applying cutting edge precision medicine approaches to understand how fundamental metabolic processes are altered in cardiometabolic disease, identifying therapeutic targets for early diagnosis, prognosis, treatment optimisation, and clinical translation of findings from bench to bedside.
Francesco Botrè, PhD
University of Lausanne, Lausanne, Switzerland

Metabolomics
Anti-Doping
Pharmacokinetics
Toxicology

Born in Rome (Italy). Chemist; pharmacist; pharmacologist. Professor at the Institute of Sport Sciences of the University of Lausanne, Switzerland, and Director of REDs (Research and Expertise on anti-Doping sciences). Director (since 1998) of the Italian antidoping laboratory accredited by the World Anti-Doping Agency, and regularly appointed as international expert on the occasion of major International Sport Events. He also directed the antidoping laboratory for the Torino 2006 Olympics and Paralympics. Author of over 300 scientific publications.
Tim Garrett, PhD
University of Florida College of Medicine, Gainesville, Florida, United States

Metabolomics
Lipidomics
Quantitative MS
Imaging

Dr. Garrett has over 20 years of experience in the field of mass spectrometry spanning both instrument and application development. He received his PhD from the University of Florida, under Dr. Richard A. Yost, working on the first imaging mass spectrometry-based ion trap instrument. He has also developed MALDI-based approaches to analyze proteins in bacteria and small molecules in tissue specimens. His current interests include the translation of LC-HRMS, MALDI, DESI and LMJSSP in metabolomics to clinical diagnostics. He is an Associate Professor in the Department of Pathology at the University of Florida, and an Associate Director for the Southeast Center for Integrated Metabolomics (SECIM).
Roland Geyer, Ph.D.
Thermo Fisher Diagnostics Switzerland, Pratteln, Basel-Country, Switzerland

Metabolomics
Lipidomics
Small Molecules
Vitamin D
Automation
Clinical Implementation

Roland started as a microbiologist where he gained method development expertise using LC-MS. At the University of Tennessee Center for Biomarker Analysis he worked on lipid biomarker analysis using LC-MS/MS and GC-MS systems, including evaluating lipids in breath condensates. In 2006, he joined a leading MS instrument provider as an Application Specialist. In 2009, he joined a company providing laboratory automation systems where he led technology feasibility and development projects for innovative extraction consumables and workflows for the clinical MS lab. In 2015, Roland joined the clinical chemistry department of the University Hospital Bern in Switzerland to gain insights into the feasibility of approaches and concepts in the clinic. Since 2017, he has been working as Business Development Manager for a large life science company in the area of Clinical MS automation. Roland has been attending MSACL since 2010 with the goal of extending the use of LC-MS diagnostic applications into the clinical lab.
Julijana Ivanisevic, PhD
University of Lausanne, Lausanne, Switzerland

Metabolomics
Lipidomics
Metabolite Role and Activity
Metabolic Sex Differences
Metabolic Phenotyping

Julijana Ivanisevic is a Metabolomics group leader and Senior Lecturer at the Faculty of Biology and Medicine, University of Lausanne. As a biologist trained in chemistry and evolving in the field of metabolomics for the past ten years, the most prominent aspect of her work constitutes the translation of mass spectrometry (MS) data into the biochemically and physiologically relevant information. The main interest of her team is to advance the knowledge on sex differences, across human polar metabolome and lipidome, in health and with the onset and progression of metabolic alterations with age.
Adam Rosebrock, PhD
Stony Brook School of Medicine, Long Island, New York, United States

Metabolomics
Data Science
Separations
Instrumentation

Adam is a biochemist and molecular biologist who frequently crosses into engineering and physical science while pursuing questions at the interface of basic science biology and translational research. His primary research focus is on understanding the genetic and cell-state regulation of small-molecule metabolism. His lab uses a combination of targeted and full-scan LC- and GC- mass spectrometry approaches to monitor metabolite levels and reaction flux to mechanistically connect genotype with metabolic phenotype. He is an active tool-builder, ranging from genetic constructs to new chromatographic separations to data processing software. He is currently an assistant professor in the Department of Pathology at Stony Brook School of Medicine and the Stony Brook University Cancer Center.
Consolato Sergi, MD, PhD
Children’s Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada

Metabolomics
Pathology
Data Science

Consolato M. SERGI is Canadian, born in Rome (Italy), who obtained his MD degree with honors (1989) and Pediatric specialization (1993) at the University of Genoa, Italy, and Pathology specialization at the University of Heidelberg, Germany (2001). He received the title of Honorary Clinical Reader at the University of Bristol, UK (2002), Ph.D. (Habilitation) at the University of Innsbruck, Austria (2004), and MSc Public Health in Austria (2007). Dr. Sergi is board certified (FRCPC) (2013). Dr. Sergi is the Chief of Pathology Laboratories Children's Hospital of Eastern Ontario, University of Ottawa.
Yuqin Wang, PhD
Swansea University, Swansea, Wales, United Kingdom
Metabolomics
Proteomics
Lipidomics

Yuqin received her BS in Pharmacy from Beijing Medical University and her PhD in Medical Biochemistry from the Karolinska Institutet. She is interested in cholesterol metabolism in humans and its relation to neurological disorders and immunity. She has extensive experience in applying mass spectrometry-based lipidomics and proteomics in studying biologically active sterols and sterol-protein interactions. She is a co-inventor of the US patent “Kit and method for quantitative detection of steroids” (US9851368B2). She has applied this technique to identify aberrant cholesterol metabolites associated with neurodegenerative diseases. She has also been involved in demonstrating that bioactive sterols are produced in the developing mouse brain and promote neurogenesis. In collaboration with Prof. William Griffiths at Swansea University, she has developed a mass spectrometry imaging platform enabling visualization of sterol spatial distribution in intact tissue. This new technique is important to fully understand how cholesterol metabolism underpins brain physiology and pathology.
Elizabeth Want, PhD
Imperial College London, London, United Kingdom
Metabolomics
Toxicology

Liz is the Waters Senior Lecturer in Molecular Spectroscopy in the Department of Surgery and Cancer. She joined Imperial College in 2006 after working as a postdoctoral researcher at the Scripps Research Institute in La Jolla, CA. At Imperial College, she was initially a postdoctoral researcher for the Consortium for Metabonomic Toxicology (COMET) group. Her research focuses primarily on the development and application of novel MS-based techniques for metabolic phenotyping and on the fusion of MS methods with chemometric analysis, which is currently a significant bottleneck in the analysis pipeline. Broadly, her research at Imperial College has involved the development, optimisation and application of UPLC-MS methodologies for the analysis of biological samples, largely in the context of metabolic phenotyping: serum, urine, tissue, amniotic fluid, and microdialysates. Liz is applying these methods to biomedical research areas including toxicology, cardiovascular disease, neonatal disease and development, maternal exposures and effects on early childhood, and neurological diseases.

Microbiology

Jean Armengaud, PhD
French Alternative Energies and Atomic Energy Commission Marcoule, Bagnols-sur-Cèze, France

Microbiology
Proteomics
Sample Prep
Pathogen Detection
Data Science
Biomarkers
Diagnostics

Jean Armengaud is expert in mass spectrometry for the identification and characterization of pathogens, and the definition of biomarkers for medical and environmental purposes. He manages a mass spectrometry research unit located near Avignon in France. His research team develops new methodologies for the study of microbiota and their clinical applications. It also exploits proteogenomics, the alliance of genomics and proteomics for the characterization of biological models and the identification of novel biomarkers. Recently, the team got involved on the COVID-19 pandemic issue and developed mss spectrometry approaches to better understand and detect the SARS-CoV-2 virus.

Proteomics

Amol Bajaj, MS
ARUP, Salt Lake City, Utah, United States

Proteomics
Toxicology
Small Molecules
Microbiology
Method Development & Validation

Amol Bajaj is a Scientist III, Mass Spectrometry R&D at ARUP Institute for Clinical and Experimental Pathology. He received his MS in Biotechnology from University of Houston Clear Lake. His key interests are the development of high-resolution mass spectrometric methods for the characterization and identification of microorganisms such as mycobacteria. He is highly passionate to develop innovative analytical strategies and make the challenging assay work in the clinical laboratory. He has strong interest towards developing and validating method for proteins and peptide biomarkers. He has over 9 years’ experience with LC-MS/MS and 6 years in clinical diagnostics.
Mustafa Barbhuiya, PhD
Quest Diagnostics/ReproSource Fertility Diagnostics, Marlborough, Massachusetts, United States

Proteomics
Biomarkers
Endocrinology
Fertility Testing

Dr. Mustafa Barbhuiya is Associate Scientific Director of Quest Diagnostics, ReproSource Esoteric Fertility Laboratory at Marlborough, MA. He is broadly trained in molecular pathology, clinical biochemistry, reproductive endocrinology, fertility diagnostics, cancer biomarkers, next generation sequencing and mass spectrometry. Mustafa enjoys deep reading, travelling, meeting people, learning about new communities and places. He keeps interest in global public health and believes in global citizenry.
David Barnidge, PhD
The Binding Site, Rochester, Minnesota, United States

Proteomics
TDM
Immunology
Hematology
Regulations & Standards

David R. Barnidge, PhD, is a mass spectrometrist specializing in the development of new ways to analyze antibodies, also called immunoglobulins. Dr. Barnidge and pathologist David L. Murray, M.D., Ph.D., invented a new methodology called monoclonal immunoglobulin Rapid Accurate Molecular Mass (miRAMM), used to diagnose patients with B cell disorders by using mass spectrometry to measure the molecular weight of the antibodies secreted by B cells. This technology provides clinicians with an individualized picture of each patient's immune system, allowing them to treat patients more effectively.
Pankaj Dwivedi, PhD
Genentech, South San Francisco, California, United States

Proteomics
Data Science

Pankaj has expertise in cancer biology, quantitative proteomics-phosphoproteomics, protein biochemistry, and proteomics data analysis. He has published seminal scientific papers on the cytokine receptor biology and its role in leukemia. His sphere of experience and interest includes but not limited to cell cultures, mouse models, processing proteomics samples and operating nano-LC-MS/MS. He has in-depth knowledge and understanding of quantitative proteomics techniques, e.g. SILAC, TMT, iTRAQ and RABA and understanding of aberrant proteomics as well as phospho-signaling and global ubiquitin profiles of solid and liquid tumor models.
Trevor Glaros, PhD
Los Alamos National Laboratory, Los Alamos, New Mexico, United States

Proteomics
Breath Analysis
Metabolomics
Ambient Ionization

Dr. Trevor Glaros is the Deputy Group Leader of the Bioenergy and Biome Sciences Group, within the Biosciences Division at the Los Alamos National Laboratory, a role he started in 2020. Before joining LANL, Dr. Glaros was a Principal Investigator at the the US Army Edgewood Chemical Biological Center in Maryland. He is an experienced researcher and classically trained molecular biologist skilled in mass spectrometry. He is one of the pioneers in paper spray ionization mass spectrometry, and championed its application towards chemical warfare agents, pesticides, and intoxicating nerve agents. Dr. Glaros is also an expert in proteomics and metabolomics and has applied these approaches to numerous biomarker discovery programs.
Oleg Karaduta, MD
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Proteomics
Metabolomics
Clinical Implementation

I started my career as a vascular surgeon back in Volgograd, Russia in 2007. However, it was science, that always excited me and after relocating to United States, I joined the lab studying vascular complication of chronic kidney disease. Gradually, I progressed to nephropathology and its microbiome aspect. That was the point when I joined the MassSpec team and fell in love with this technology. Nowadays, I can see how thousands of brilliant scientists use this tool in their research, making it truly exciting. And this is only beginning.
Theodora Katsila, PhD
National Hellenic Research Foundation, Athens, Greece

Proteomics
Pharmacogenomics
Toxicology
Metabolomics

Dr. Katsila did her undergraduate training in Biochemistry with a Year in Industry/Research at Imperial College London, UK and postgraduate studies in Clinical Biochemistry & Molecular Diagnostics at the National & Kapodistrian University of Athens, Greece. She received her PhD in Chemistry from the Biomedical Research Foundation Academy of Athens, Greece and University of Patras, Greece. After postdoctoral research at the University of Patras, Greece and close tights with industry, she joined Vall d’Hebron Institute of Oncology, Spain. Craving for brain teasers and driven by interdisciplinary approaches, her research interests span LC-MSn and translational biomarkers. Dr. Katsila is a Research Assistant Professor at the National Hellenic Research Foundation, Greece.
Olgica Trenchevska, PhD
Cowper Sciences, Chandler, Arizona, United States
Proteomics
MALDI
PTMs

I have obtained a degree as an Engineer in Chemistry focusing on analytical biochemistry, followed by a masters and PhD in Biochemistry (SS Cyril and Methodius University, N Macedonia) with a major focus on clinical proteomics and MALDI mass spectrometry. I have furthered my experience in a clinical laboratory (Clinic of Neurology), academia (The Biodesign Institute, ASU) and Industry (HealthTell Inc ). I am fascinated by mass spectrometry and the unambiguity it possess. I am currently a Senior Scientist at Cowper Sciences Inc, where I am focusing on exploring/applying novel methods and techniques in proteomics research, with potential for operation and commercialization.
René Zahedi, PhD
Jewish General Hospital, Montreal, Quebec, Canada

Proteomics
Method Development & Validation
Data Science
Sample Prep

Dr. Zahedi is currently the Associate Director of the Segal Cancer Proteomics Centre at the Jewish General Hospital in Montreal and Associate Member of the McGill Centre for Translational Research in Cancer. He received his PhD from the University of Wuerzburg/Germany in 2008 for his work on the phosphoproteome of human platelets. He was later a junior and then a senior PI at the Leibniz-Institute for Analytical Sciences in Dortmund, Germany. His research focuses on the analysis of clinical samples and PTMs using protein mass spectrometry.
Yusheng Zhu, PhD, DABCC, FAACC
Pennsylvania State University College of Medicine, Hershey, Pennsylvania, United States

Proteomics
Metabolomics
Imaging
Pathology
Endocrinology
Small Molecules
TDM
Toxicology

Yusheng is Professor of Pathology and Pharmacology and Medical Director of Automated Testing Laboratory, Co-Director of Pathology Core Reference Laboratory, and Director of Postdoctoral Clinical Chemistry Training Program at Penn State University Hershey Medical Center. He is board certified by ABCC in Clinical Chemistry, Toxicological Chemistry, and Molecular Diagnostics and a Fellow of the AACC Academy. Currently, he is the Vice President of ABCC, Member of AACC Academy Council, Chair of AACC Academy Council Laboratory Utilization Task Force, and Chair of Mass Spectrometry & Separation Science Division. He is interested in research in clinical chemistry, toxicology, and clinical application of mass spectrometry.

Regulations & Standards

Hubert Vesper, PhD
Centers for Disease Control and Prevention, Atlanta, Georgia, United States
Regulations & Standards
Endocrinology
Sample Prep

Hubert W. Vesper, Ph.D., is the director of the Clinical Standardization Programs at the Centers for Disease Control and Prevention’s (CDC) National Center for Environmental Health. He leads CDC’s clinical laboratory standardization programs to improve the diagnosis, treatment, and prevention of selected chronic diseases and oversees and represents specific biomonitoring programs to assess human exposure to environmental chemicals and its potential impact on human health. He also is co-chair of the steering committee of the Partnership for Accuracy in Tests for Hormones (PATH), a member of the steering committee of the National Glycohemoglobin Standardization Program, and an adjunct faculty member in the Nutrition and Health Sciences Program at Emory University. Previously he was a consultant at the Kuwait Institute for Scientific Research, co-chair of the Cardiovascular Biomarker Standardization Steering Committee, and a member of the World Health Organization (WHO)/Pan American Health Organization/CDC Emergency Response Team. He received his B.S. in food science and M.Sc. in food chemistry from the University of Karlsruhe, Germany, and his Ph.D. from the Technical University of Munich, Germany.

Small Molecules

James Hawley, MS
Wythenshawe Hospital, Manchester, United Kingdom
Small Molecules
Steroids
Metabolomics
Method Development & Validation
Clinical Implementation

I work as a Principal Clinical Scientist at Wythenshawe Hospital, Manchester, UK and I'm also currently undertaking a PhD at the University of Birmingham, UK. I have over 7 years experience with LC-MS/MS and 10 years in clinical diagnostics. In my day-to-day role I develop new LC-MS/MS assays for routine clinical use and help troubleshoot our existing assays. My PhD is looking at using mass spectrometry in combination with machine learning to interrogate the steroid metabolome in order to improve the diagnosis of adrenal cortical carcinoma.
Liam Heaney, PhD
Loughborough University, Loughborough, United Kingdom

Small Molecules
Toxicology
Quantitative MS
Biomarkers
Metabolomics
Breath Analysis
Anti-Doping

Dr Liam Heaney is a Lecturer in Bioanalytical Science at Loughborough University. His research interests include high-throughput measurement of small molecule biomarkers. This includes active projects that span across multiple disciplines including clinical diagnostic and prognostic applications and sports anti-doping/drugs of abuse. His work is centered around the application of analytical chemistry applying both gas chromatography and liquid chromatography-mass spectrometry. Prior to his current position, Liam spent time as a postdoctoral researcher at the University of Leicester’s NIHR Cardiovascular Biomedical Research Centre where he specialized in the analysis of cardiovascular disease biomarkers using MS-based techniques.
Chia-Ni Lin, PhD
Chang Gung Memorial Hospital, Taoyuan, Taiwan

Small Molecules

Dr. Chia-Ni Lin is Associate Director in the Department of Laboratory Medicine at Chang Gung Memorial Hospital and Adjunct Assistant Professor at Chang Gung University. She received her Ph.D. degree in Clinical Laboratory Sciences and Medical Biotechnology from National Taiwan University followed by a fellowship in Clinical Chemistry at ARUP/University of Utah. She is board certificated by the American Board of Clinical Chemistry and a fellow of AACC academy. Her research interests are development, method improvement and validation of clinical laboratory assays, and mass spectrometry applications in clinical laboratory including metabolites in biological fluids, illicit drugs, trace elements and hormones.
Grace van der Gugten
St Paul's Hospital, Vancouver, British Columbia, Canada

Small Molecules
Clinical Implementation

Grace is the LC-MS/MS Assay Development Specialist in the clinical chemistry laboratory at St Paul’s Hospital in Vancouver, BC, Canada. Grace has a BSc in Chemistry from The King’s University College and spent 5 years doing bioanalytical LC-MS/MS lab work prior to her work in the clinical laboratory setting. She is passionate about mass spectrometry and that this technology is utilized in the clinical lab to help patients. Grace has a strong interest in troubleshooting and making challenging assays work for a busy clinical mass spectrometry laboratory.

TDM

Jan-Willem Alffenaar, PhD, PharmD
University of Sydney, Sydney, Australia

TDM
Toxicology
Infectious Disease
Dried Blood Spots
Transplant Medicine
Point-of-Care

Jan-Willem started his career in research during his residency in hospital pharmacy. After completion of his residency and PhD he remained involved in research. In addition to his clinical activities as hospital pharmacist in a tertiary care teaching hospital he was involved in several hospital activities. He was member of the antimicrobial drug committee and he chaired the PK/PD subcommittee. He served as hospital pharmacist as well as clinical pharmacologist the the Institutional Review Board evaluation medical research protocols. He also had a role in building a GCP certified framework for medical research in the hospital as co-chair of the drug trials committee. Internationally, he served on several committees on therapeutic drug monitoring in infectious diseases and alternative sampling strategies for therapeutic drug monitoring. Besides hosting several national and international symposia he has been frequently asked as invited speaker on international conferences, particularly in the field of tuberculosis and therapeutic drug monitoring.
Peter Galettis, PhD
University of Newcastle, Callaghan, New South Wales, Australia

TDM
Small Molecules
Ambient Ionization
Toxicology
Instrumentation

Dr Galettis currently holds the position of Head of the Clinical Pharmacology Laboratory at the University of Newcastle. He has previously held senior laboratory roles in academia, pathology and hospital settings where he was responsible for the development and implementation of new assays. Dr Galettis's research interests are entirely within the field of clinical pharmacology and toxicology, specialising in assay development for use in drug monitoring for the last 30 years, focussing on anticancer agents and drugs of abuse.
Kamisha Johnson-Davis, PhD
University of Utah and ARUP, Salt Lake City, Utah, United States
TDM
Toxicology
Clinical Implementation
Regulations & Standards

Dr. Johnson-Davis is an Associate Professor (Clinical) at the University of Utah in the Department of Pathology and a Medical Director for Clinical Toxicology at ARUP Laboratories. She received her B.S. degree in Biochemistry from the University of California, Riverside and her Ph.D. in Pharmacology from the University of Utah. She was a postdoctoral research associate at the Center for Human Toxicology and she completed a postdoctoral fellowship in clinical chemistry at the University of Utah, Department of Pathology. Dr. Johnson-Davis is board certified by the American Board of Clinical Chemistry in Clinical Chemistry in Clinical Chemistry and Toxicological Chemistry and she is the Director for the Clinical Chemistry Fellowship Program at the University of Utah.
Katherina Rentsch, PhD, Prof. Dr. sc. nat
Universitätsspital Basel, Basel, Switzerland

TDM
Toxicology
Regulations & Standards

Katharina Rentsch studied pharmacy at the ETH in Zurich. After certification as specialist for laboratory medicine FAMH for clinical chemistry and clinical immunology she finished her PhD thesis on therapeutic drug monitoring of cytostatic drugs at the ETH Zurich in 1996. In 2010 she became an adjunct professor at the medical faculty of the University Zurich, in 2012 at the medical faculty of the University Basel. She is head of the department for laboratory medicine and the division of Clinical Chemistry at the University Hospital Basel, Switzerland. The main research interests of Katharina Rentsch are the development of new analytical methodologies for therapeutic drug monitoring and clinical toxicology and their application in different clinical studies as well as the implementation of TDM procedures for new drugs.
Jody van den Ouweland, PhD
Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands

TDM
Endocrinology
Small Molecules
Vitamins
Steroids

Jody van den Ouweland is specialist in Laboratory Medicine and working as Laboratory Director at the Canisius-Wilhelmina Hospital, The Netherlands. He studied Chemistry at Leiden University and received his PhD degree in 1994 on the discovery of a type 2 diabetic subtype (MIDD). Areas of clinical interest are diabetes, endocrinology and clinical biomarkers. In the area of analytical chemistry his focus is on mass spectrometric and chromatographic methods for quantitative measurement of low molecular weight biomarkers, such as vitamins, steroids and amino acids. He is a member of the Dutch working group of Clinical Mass Spectrometry, member of the MSACL EU Scientific Board, and Editorial Board member of the Journal of Mass Spectrometry & Advances in the Clinical Lab.
Michael Vogeser, Prof. Dr. med.
University Hospital, LMU Munich, Munich, Germany

TDM
Clinical Implementation
Diagnostics
Endocrinology
Risk Management

Dr. Michael Vogeser, MD, is specialist in Laboratory Medicine and senior physician at the Hospital of the University of the Ludwig-Maximilians-University Munich, Germany (LMU; Institute of Laboratory Medicine). As an Associate Professor he is teaching Clinical Chemistry and Laboratory Medicine. The main scope of his scientific work is the application of mass spectrometric technologies in routine clinical laboratory testing as translational diagnostics. Besides method development in therapeutic drug monitoring and endocrinology a further particular field of his work is quality and risk management in mass spectrometry and in clinical testing in general. Michael has published >150 articles in peer reviewed medical journals.

Toxicology

Mahesheema Ali, PhD, NRCC
The MetroHealth Medical Center, Cleveland, Ohio, United States

Toxicology
Pathology
Automation
TDM
Newborn Screening
Method Development & Validation

Dr. Mahesheema Ali is Section Head of Clinical Chemistry, Toxicology & POCT at The Metro Health Systems and Assistant Professor of Clinical Science at Case Western Reserve University School of Medicine. She received her Ph.D. degree in Clinical-Bioanalytical Chemistry from the Cleveland State University and Clinical Chemistry fellowship from Baylor College of Medicine / Texas Children’s Hospital. She is a member and actively involved in professional associations such as the American Association for Clinical Chemistry (AACC) and The College of American Pathologists (CAP). Her primary interests include laboratory management& Utilization, development and validation of LC-MS/MS, pediatric clinical chemistry, and implementation of precision medicine.
Melissa Budelier, PhD
Washington University in St Louis, St Louis, Missouri, United States
Toxicology
TDM
Clinical Implementation
Method Development & Validation
Proteomics
Small Molecules
Biomarkers
Diagnostics

Dr. Budelier is an Instructor in Pathology and Immunology at Washington University in St Louis, and is a Co-Medical Director of the Barnes Jewish Hospital Toxicology Laboratory. Her research interests are broadly focused on developing clinically useful, mass spectrometry-based assays to improve diagnosis and treatment of human disease. Her expertise are in Toxicology/TDM, assay development and validation, and protein quantification.
Chi-Wei Lee, MD, PhD
Institute of Medical Science and Technology, National Sun Yat-Sen University, Kaohsiung City, Taiwan

Toxicology
Ambient Ionization
Method Development & Validation
Clinical Implementation

Dr. Lee received his M.D. and Ph.D. from the Kaohsiung Medical University in 1992 and 2016, respectively. With three specialty board certifications (viz. Internal Medicine, Emergency Medicine, Critical Care Medicine), he was in-charge-of the Emergency Department (Medical Division), Kaohsiung Medical University Hospital. As an Assistant Professor (Institute of Medical Science and Technology, National Sun Yat-Sen University), his research interest remains the development of efficacious techniques (both diagnostic and therapeutic) capable of improving the quality of patient care. For a decade, he has been focusing on the clinical applications of ambient mass spectrometry in the rapid identification of toxicants/toxins causing acute poisoning.
Kara Lynch, PhD
University of California San Francisco, San Francisco, California, United States

Toxicology
TDM
HRMS
SPR
Thin Film Interferometry

Dr. Kara Lynch is an Associate Professor of Laboratory Medicine at the University of California San Francisco, Co-Director of the Core Laboratory at Zuckerberg San Francisco General Hospital, and Chemistry Director at UCSF Benioff Children’s Hospital Oakland. She received her PhD in Biochemistry from the University of Wisconsin and did a post-doctoral fellowship in Clinical Chemistry at UCSF. Her laboratory conducts studies aimed at identifying and quantifying endogenous and exogenous small molecules using novel diagnostic technologies, such as high resolution mass spectrometry, direct to mass spec technologies, and thin-film interferometry label-free immunoassays, and correlating findings with clinical pathologies.
Stephanie Marin, PhD
Biotage, Salt Lake City, Utah, United States

Toxicology
Sample Prep
Clinical Implementation

I have ten years of experience developing and validating LC-MS assays at the ARUP Institute for Clinical and Experimental Pathology. I have over 30 peer-reviewed publications and book chapters, and have presented over 100 abstracts at national meetings. I have expertise in liquid chromatography, LC-MS/MS, and high resolution MS. I have been a chairperson and presenter for workshops on clinical MS at AACC, SOFT and MSACL. I am a member of SOFT, ASMS, ACS and AACC. I have been a reviewer for several journals, including Journal of Chromatography B, Journal or Analytical Toxicology, and this journal. I have also been a reviewer for SOFT and AACC national meeting abstracts.
Gwen McMillin, PhD
University of Utah and ARUP, Salt Lake City, Utah, United States

Toxicology
Pharmacogenomics
Analytical Methods

Gwen McMillin is a Professor of Clinical Pathology at the University of Utah School of Medicine and a Medical Director of Mass Spectrometry, Clinical Toxicology and Pharmacogenomics at ARUP Laboratories in Salt Lake City, Utah, USA. She received a PhD in pharmacology and toxicology from the University of Utah and received post-doctoral training in clinical chemistry. She is certified by the American Board of Clinical Chemistry in clinical and toxicological chemistry. Her primary interests include clinical applications of drug and toxicant testing, as well as analytical methods and pharmacogenomics.
Stephen Roper, PhD
Washington University of School of Medicine & St. Louis Children's Hospital, St Louis, Missouri, United States

Toxicology
Glycoproteomics
Small Molecules
TDM
Newborn Screening
Proteomics

My graduate studies centered on proteomic and glycoproteomic biomarker discovery in NSCLC. During this time, I gained experience with techniques such as Click chemistry and SILAC, as well as tissue imaging of N-linked glycans. In 2017 I completed a clinical chemistry postdoctoral fellowship where I focused on maternal and pediatric laboratory medicine, including the development and validation of HPLC and LC-MS/MS amino acid, adrenal steroid, and TDM assays. In 2017, I took a position at Washington University in St. Louis. Here, my work includes shared oversight of the clinical laboratory at St. Louis Children's Hospital and the toxicology section at Barnes Jewish Hospital.
Victoria Zhang, PhD, MBA
University of Rochester Medical Center, Rochester, New York, United States

Toxicology
Small Molecules
Proteomics
Instrumentation

Started my career in proteomics for biomarker discovery from graduate school where I also got my bioinformatic minor to handle all the data i generated. Later moved to clinical chemistry and continue to focus on mass spectrometry applications in clinical labs. Started a division within AACC to establish a platform in AACC for this technology. Have attended numerous short courses, workshops and symposia and conference in the past few years for mass spectrometry. Looking forward to do what I can to further this field!